Harbour Bio to Start China Trials of CLTA-4/PD-1 Combo in Two Additional Cancers
publication date: Sep 14, 2021
Harbour BioMed was approved to start China trials of its next-gen CLTA-4 candidate in combination with its PD-1 for two new indications: hepatocellular carcinoma and neuroendocrine tumor/neuroendocrine carcinoma. HBM believes HBM4003, a fully human anti-CTLA-4 mAb, has the potential to improve efficacy while reducing toxicity as a monotherapy and combo-therapy. Earlier this year, the CLTA-4/PD-1 combination started China trials for NSCLC. Harbour is headquartered in Cambridge, MA, with discovery operations in Rotterdam and development labs in Suzhou. More details....
Stock Symbol: (HK: 02142)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.